BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Replimune\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Replimune\, Inc.'s drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05733598-10918@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Sturlimogene erparepvec: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Sturlimogene erparepvec\, phase 2.\nStudy: Study of RP2 in Comb
 ination With Second-line Therapy in Patients With Locally Advanced or Meta
 static HCC\nEstimated primary completion: 1 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-2713@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 2 readout est. (NCT0376
 7348)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 2\, Non-Small Cell
  Lung Cancer.\nStudy: Study of RP1 Monotherapy and RP1 in Combination With
  Nivolumab (IGNYTE)\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqe
 v#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 767348
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04349436-2713@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 1/2 readout est. (NCT04
 349436)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 1/2.\nStudy: Study
  to Investigate the Efficacy and Safety of RP1 in Adult Patients With Orga
 n Transplants and Advanced Skin Malignancies\nEstimated primary completion
 : July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vusolimo
 gene-oderparepvec-tudriqev#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04349436
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-10918@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Sturlimogene erparepvec: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Sturlimogene erparepvec\, phase 2/3\, Uveal Melanoma.\nStudy: A
  Randomized\, Phase 2/3 Study to Investigate the Efficacy and Safety of RP
 2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adul
 t Patients With Metastatic Uveal Melanoma\nEstimated primary completion: J
 anuary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sturlimo
 gene-erparepvec#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06581406
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
